|Day Low/High||2.77 / 2.82|
|52 Wk Low/High||1.58 / 4.09|
We beat the benchmark Russell 2000 for the quarter, and we await a busy week on the economic front.
We are keeping an eye on rate-sensitive names for possible buying opportunities, as stocks fell around 1.5% this week.
Investors in Antares Pharma Inc. saw new options begin trading this week, for the November 17th expiration.
We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.
With the stock jumping on 4Q results, we'll lower our rating.
We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.
We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.
We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.
We closed out our position in OraSure Technologies for an average gain of 105% gain.
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
We're initiating a position in drug-delivery system developer Antares Pharma, which we think can double from current levels.
While there are many reasons why insiders may sell a stock, there's really only one reason they purchase on the open market -- to make money.
The Company's First New Drug Application Utilizing QuickShot® Technology
Investors in Antares Pharma Inc. saw new options begin trading this week, for the August 2017 expiration.
Teriparatide Injection Represents the First Product Approved in Europe Utilizing Antares' Multi-Dose Pen Technology
Record Product Sales Drive Third Quarter Results
QuickShot® Testosterone Data Has Been Selected for Both Oral and Poster Presentations
Analysis of 26 Week Safety Data From Study QST-15-005 Completed, NDA Submission Remains on Track for Fourth Quarter 2016
The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.
Significant Growth in Product Sales Drive Second Quarter Results
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.